A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in the UK and Ireland (RETRO‐idel)

Idelalisib (IDL) is an oral first‐in‐class phosphatidylinositol 3‐kinase delta (PI3Kδ) inhibitor approved for chronic lymphocytic leukaemia (CLL) alongside rituximab (R) since 2014. However, little data exist on routine practice. The RETRO‐idel was a protocol‐led, retrospective study of 110 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Eyre, Toby A., Preston, Gavin, Kagdi, Huseini, Islam, Amin, Nicholson, Toby, Smith, Harry W., Cursley, Adam P., Ramroth, Heribert, Xing, Guan, Gu, Lin, Rajakumaraswamy, Nishanthan, Fegan, Christopher
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Haematological malignancy ‐ Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361941/
https://www.ncbi.nlm.nih.gov/pubmed/34121184
http://dx.doi.org/10.1111/bjh.17475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361941/
https://www.ncbi.nlm.nih.gov/pubmed/34121184
http://dx.doi.org/10.1111/bjh.17475

Ejemplares similares